Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 23 | 2021 | 635 | 2.410 |
Why?
|
| Influenza, Human | 22 | 2021 | 925 | 1.970 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 8 | 2015 | 68 | 1.180 |
Why?
|
| Antibodies, Viral | 18 | 2021 | 1320 | 0.690 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 3 | 2021 | 25 | 0.680 |
Why?
|
| Vaccines, Inactivated | 12 | 2020 | 175 | 0.680 |
Why?
|
| Immunogenicity, Vaccine | 4 | 2021 | 86 | 0.580 |
Why?
|
| Adjuvants, Immunologic | 11 | 2023 | 657 | 0.570 |
Why?
|
| Immunization, Secondary | 8 | 2019 | 110 | 0.540 |
Why?
|
| Hemagglutination Inhibition Tests | 8 | 2021 | 159 | 0.400 |
Why?
|
| Zika Virus Infection | 3 | 2019 | 166 | 0.400 |
Why?
|
| Vaccination | 10 | 2019 | 1123 | 0.390 |
Why?
|
| Immunization Schedule | 4 | 2017 | 117 | 0.330 |
Why?
|
| Squalene | 5 | 2021 | 21 | 0.320 |
Why?
|
| Zika Virus | 3 | 2019 | 144 | 0.320 |
Why?
|
| Double-Blind Method | 13 | 2019 | 2588 | 0.310 |
Why?
|
| Vaccines | 4 | 2019 | 389 | 0.310 |
Why?
|
| Vaccines, DNA | 2 | 2019 | 105 | 0.290 |
Why?
|
| RNA, Viral | 3 | 2019 | 671 | 0.290 |
Why?
|
| Injections, Intradermal | 4 | 2019 | 58 | 0.270 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2018 | 419 | 0.250 |
Why?
|
| Injections, Intramuscular | 4 | 2015 | 255 | 0.250 |
Why?
|
| Aluminum Hydroxide | 3 | 2023 | 40 | 0.230 |
Why?
|
| Schistosomiasis mansoni | 1 | 2023 | 30 | 0.230 |
Why?
|
| Young Adult | 21 | 2020 | 21445 | 0.220 |
Why?
|
| Polysorbates | 5 | 2021 | 25 | 0.220 |
Why?
|
| Influenza A Virus, H7N7 Subtype | 2 | 2019 | 14 | 0.200 |
Why?
|
| Hemagglutinins | 2 | 2019 | 39 | 0.200 |
Why?
|
| Antibodies, Neutralizing | 5 | 2019 | 541 | 0.190 |
Why?
|
| Lipid A | 1 | 2019 | 30 | 0.180 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 2 | 2011 | 17 | 0.180 |
Why?
|
| Antibodies, Helminth | 1 | 2019 | 105 | 0.170 |
Why?
|
| Adult | 29 | 2020 | 77950 | 0.170 |
Why?
|
| Schistosomiasis | 1 | 2019 | 63 | 0.170 |
Why?
|
| Glucosides | 1 | 2019 | 64 | 0.170 |
Why?
|
| Adolescent | 18 | 2020 | 31252 | 0.170 |
Why?
|
| alpha-Tocopherol | 2 | 2015 | 78 | 0.170 |
Why?
|
| Information Services | 1 | 2018 | 50 | 0.160 |
Why?
|
| Vagina | 2 | 2019 | 317 | 0.160 |
Why?
|
| Body Fluids | 1 | 2019 | 125 | 0.160 |
Why?
|
| Antibodies, Bacterial | 2 | 2017 | 380 | 0.160 |
Why?
|
| Tularemia | 1 | 2017 | 12 | 0.150 |
Why?
|
| Francisella tularensis | 1 | 2017 | 19 | 0.150 |
Why?
|
| HIV Infections | 2 | 2021 | 2134 | 0.150 |
Why?
|
| Female | 35 | 2021 | 141928 | 0.150 |
Why?
|
| Bacterial Vaccines | 1 | 2017 | 103 | 0.150 |
Why?
|
| Vaccinia virus | 1 | 2017 | 79 | 0.150 |
Why?
|
| Immunity, Heterologous | 1 | 2016 | 2 | 0.150 |
Why?
|
| Smallpox Vaccine | 1 | 2017 | 43 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2019 | 3639 | 0.150 |
Why?
|
| Adaptive Immunity | 1 | 2018 | 149 | 0.140 |
Why?
|
| Cytomegalovirus Vaccines | 1 | 2015 | 7 | 0.140 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2016 | 73 | 0.140 |
Why?
|
| Drug Carriers | 1 | 2017 | 327 | 0.130 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2014 | 12 | 0.130 |
Why?
|
| Anthrax Vaccines | 1 | 2014 | 26 | 0.130 |
Why?
|
| Anthrax | 1 | 2014 | 36 | 0.120 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 1294 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 582 | 0.120 |
Why?
|
| Immunoglobulin G | 4 | 2023 | 1021 | 0.120 |
Why?
|
| Viral Envelope Proteins | 1 | 2015 | 207 | 0.120 |
Why?
|
| Meningoencephalitis | 1 | 2014 | 24 | 0.120 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2015 | 152 | 0.120 |
Why?
|
| Middle Aged | 21 | 2021 | 86204 | 0.120 |
Why?
|
| Humans | 39 | 2023 | 261506 | 0.120 |
Why?
|
| Healthy Volunteers | 3 | 2019 | 187 | 0.120 |
Why?
|
| Male | 25 | 2019 | 123000 | 0.120 |
Why?
|
| Immunity, Cellular | 1 | 2015 | 419 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2018 | 677 | 0.110 |
Why?
|
| Pregnancy | 8 | 2020 | 7573 | 0.110 |
Why?
|
| Neutralization Tests | 4 | 2017 | 299 | 0.110 |
Why?
|
| Immunization | 1 | 2014 | 397 | 0.110 |
Why?
|
| Blood Chemical Analysis | 1 | 2013 | 118 | 0.110 |
Why?
|
| Influenza in Birds | 1 | 2012 | 26 | 0.110 |
Why?
|
| Communicable Disease Control | 1 | 2014 | 175 | 0.110 |
Why?
|
| Health Personnel | 1 | 2018 | 625 | 0.110 |
Why?
|
| Picornaviridae | 1 | 2011 | 24 | 0.100 |
Why?
|
| Cytomegalovirus Infections | 1 | 2015 | 462 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 362 | 0.100 |
Why?
|
| Schistosoma mansoni | 2 | 2023 | 36 | 0.100 |
Why?
|
| Picornaviridae Infections | 1 | 2011 | 57 | 0.100 |
Why?
|
| Chagas Disease | 1 | 2014 | 277 | 0.090 |
Why?
|
| Apolipoproteins E | 1 | 2011 | 221 | 0.090 |
Why?
|
| Warfarin | 1 | 2011 | 152 | 0.090 |
Why?
|
| China | 1 | 2021 | 606 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 242 | 0.090 |
Why?
|
| Hospitalization | 2 | 2021 | 2083 | 0.080 |
Why?
|
| Aged | 12 | 2021 | 70117 | 0.080 |
Why?
|
| Seasons | 2 | 2020 | 340 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 2011 | 437 | 0.080 |
Why?
|
| Dose-Response Relationship, Immunologic | 3 | 2015 | 182 | 0.070 |
Why?
|
| Saliva | 2 | 2019 | 231 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 3719 | 0.070 |
Why?
|
| Research Design | 1 | 2013 | 1544 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2011 | 787 | 0.070 |
Why?
|
| Placebos | 2 | 2015 | 437 | 0.060 |
Why?
|
| Cytokines | 3 | 2019 | 2809 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2015 | 621 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 3869 | 0.060 |
Why?
|
| Vero Cells | 2 | 2017 | 143 | 0.060 |
Why?
|
| Brazil | 1 | 2023 | 165 | 0.060 |
Why?
|
| Protozoan Vaccines | 1 | 2023 | 91 | 0.050 |
Why?
|
| Time Factors | 4 | 2018 | 12926 | 0.050 |
Why?
|
| Animals | 6 | 2023 | 59536 | 0.050 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2013 | 186 | 0.050 |
Why?
|
| Age Factors | 3 | 2015 | 5377 | 0.050 |
Why?
|
| HIV | 1 | 2021 | 229 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2019 | 190 | 0.040 |
Why?
|
| Pregnant Women | 1 | 2020 | 162 | 0.040 |
Why?
|
| Antigens, Helminth | 1 | 2019 | 178 | 0.040 |
Why?
|
| Semen | 1 | 2019 | 90 | 0.040 |
Why?
|
| Agglutination Tests | 1 | 2017 | 7 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 275 | 0.040 |
Why?
|
| Seroconversion | 1 | 2017 | 19 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 4938 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 245 | 0.040 |
Why?
|
| Viral Plaque Assay | 1 | 2017 | 48 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2017 | 23 | 0.040 |
Why?
|
| Honduras | 1 | 2017 | 21 | 0.040 |
Why?
|
| Vaccines, Attenuated | 1 | 2017 | 210 | 0.040 |
Why?
|
| Demography | 1 | 2018 | 435 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 347 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2017 | 334 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2017 | 260 | 0.040 |
Why?
|
| Milk, Human | 1 | 2019 | 277 | 0.040 |
Why?
|
| Infant | 3 | 2020 | 13310 | 0.040 |
Why?
|
| Hemagglutination, Viral | 1 | 2015 | 10 | 0.030 |
Why?
|
| Viral Load | 1 | 2018 | 493 | 0.030 |
Why?
|
| Granzymes | 1 | 2015 | 91 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2013 | 8223 | 0.030 |
Why?
|
| Urine | 1 | 2015 | 143 | 0.030 |
Why?
|
| Travel | 1 | 2017 | 190 | 0.030 |
Why?
|
| United States | 3 | 2018 | 15433 | 0.030 |
Why?
|
| Blood | 1 | 2015 | 156 | 0.030 |
Why?
|
| Vaccines, Subunit | 1 | 2015 | 124 | 0.030 |
Why?
|
| Tetanus | 1 | 2014 | 25 | 0.030 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2014 | 48 | 0.030 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2014 | 4 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2014 | 32848 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2020 | 12873 | 0.030 |
Why?
|
| Trypanocidal Agents | 1 | 2014 | 26 | 0.030 |
Why?
|
| Cross Reactions | 1 | 2015 | 266 | 0.030 |
Why?
|
| Immunization Programs | 1 | 2014 | 73 | 0.030 |
Why?
|
| Whooping Cough | 1 | 2014 | 62 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 2015 | 355 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 29902 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2015 | 471 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 2170 | 0.030 |
Why?
|
| Nitroimidazoles | 1 | 2014 | 100 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 1489 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2015 | 694 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2019 | 9244 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 709 | 0.030 |
Why?
|
| Birds | 1 | 2012 | 92 | 0.030 |
Why?
|
| Virus Cultivation | 1 | 2011 | 70 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2012 | 383 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 918 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2015 | 1144 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2011 | 137 | 0.020 |
Why?
|
| Trypanosoma cruzi | 1 | 2014 | 221 | 0.020 |
Why?
|
| Reference Values | 1 | 2013 | 1099 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 350 | 0.020 |
Why?
|
| Pharmacists | 1 | 2011 | 95 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 598 | 0.020 |
Why?
|
| Australia | 1 | 2010 | 225 | 0.020 |
Why?
|
| Viruses | 1 | 2011 | 159 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 260 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 3203 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 649 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 6311 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 5687 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 4744 | 0.020 |
Why?
|
| Safety | 1 | 2006 | 465 | 0.020 |
Why?
|
| Prevalence | 1 | 2011 | 3260 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2016 | 7226 | 0.010 |
Why?
|
| Genotype | 1 | 2011 | 4109 | 0.010 |
Why?
|
| Child | 2 | 2015 | 29154 | 0.010 |
Why?
|
| Mice | 1 | 2023 | 34495 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 14889 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2011 | 16273 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 37905 | 0.010 |
Why?
|